RVMD
Revolution Medicines, Inc.
Price Chart
Latest Quote
$162.99
+5.22 (+3.31%)
Current Price
| Previous Close | $157.77 |
| Open | $160.94 |
| Day High | $164.78 |
| Day Low | $158.44 |
| Volume | 4,702,503 |
Stock Information
| Shares Outstanding | 212.60M |
| Total Debt | $437.27M |
| Cash Equivalents | $1.91B |
| Net Income | $-1.37B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $34.65B |
| EPS (TTM) | $-7.11 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $33.18B |
| Income | $-1.37B |
| Book/sh | $7.49 |
| Cash/sh | $8.98 |
| Employees | 883 |
Financial Ratios
| Quick Ratio | 6.59 |
| Current Ratio | 6.79 |
| Debt/Eq | 29.15 |
Returns & Margins
| ROA | -37.53% |
| ROE | -76.67% |
Ownership
| Insider Ownership | 1.89% |
| Institutional Ownership | 95.66% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -28.58 |
| P/B | 21.75 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $187.29 |
Technical Indicators
| SMA20 | $154.20 |
| SMA50 | $146.50 |
| SMA200 | $95.18 |
| RSI | 54.38 |
| ATR | 7.0474 |
| Shares Float | 194.17M |
| Short Float | 5.76% |
| Short Ratio | 4.52 |
| Volatility | 1.41 |
| Rel Volume | 1.57 |
Performance History
| Week | +9.22% |
| Month | +10.65% |
| Quarter | +64.16% |
| 6 Months | +110.15% |
| YTD | +106.26% |
| Year | +316.43% |
| 3 Years | +537.18% |
| 5 Years | +375.61% |
| 10 Years | +463.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $162.99 | 4,702,500 |
| 2026-06-17 | $157.77 | 2,227,400 |
| 2026-06-16 | $156.58 | 2,523,700 |
| 2026-06-15 | $160.06 | 2,131,800 |
| 2026-06-12 | $153.87 | 1,580,700 |
| 2026-06-11 | $149.23 | 2,202,000 |
| 2026-06-10 | $144.19 | 3,283,100 |
| 2026-06-09 | $149.55 | 2,766,700 |
| 2026-06-08 | $148.49 | 2,734,800 |
| 2026-06-05 | $149.23 | 2,140,400 |
| 2026-06-04 | $155.69 | 2,609,300 |
| 2026-06-03 | $155.99 | 2,008,000 |
| 2026-06-02 | $151.31 | 3,750,400 |
| 2026-06-01 | $163.68 | 6,730,900 |
| 2026-05-29 | $157.48 | 6,660,400 |
| 2026-05-28 | $154.63 | 2,650,700 |
| 2026-05-27 | $153.00 | 2,879,600 |
| 2026-05-26 | $154.89 | 2,393,200 |
| 2026-05-22 | $151.56 | 1,933,000 |
| 2026-05-21 | $153.73 | 1,846,200 |
| 2026-05-20 | $150.33 | 2,402,300 |
| 2026-05-19 | $147.30 | 1,995,700 |
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
đ° Latest News
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
Insider Monkey âĸ 2026-06-13T19:30:08Z
Daraxonrasibâs Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
Simply Wall St. âĸ 2026-06-12T00:23:37Z
Can Revolution Medicines Be a Game-Changer Stock?
Motley Fool âĸ 2026-06-11T11:05:00Z
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Zacks âĸ 2026-06-09T16:44:00Z
Tango Therapeutics stock surges on pancreatic cancer trial data
Quartz âĸ 2026-06-09T13:31:57Z
Tango Therapeutics Stock Soars 53% After âUnprecedentedâ Data on Pancreatic Cancer Treatment
Barrons.com âĸ 2026-06-08T20:08:00Z
Tango Skyrockets On Eye-Popping Pancreatic Cancer Results
Investor's Business Daily âĸ 2026-06-08T20:05:33Z
đ Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data
The Wall Street Journal âĸ 2026-06-08T18:28:10Z
Top Midday Gainers
MT Newswires âĸ 2026-06-08T17:58:59ZErasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
Simply Wall St. âĸ 2026-06-08T16:12:17Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $11,580,000 | $35,380,000 |
| Operating Revenue | $0 | $0 | $11,580,000 | $35,380,000 |
| Expenses | ||||
| Interest Expense | $24,231,000 | $0 | $0 | $0 |
| Total Expenses | $1,182,369,000 | $689,524,000 | $498,765,000 | $293,659,000 |
| Other Income Expense | $-15,395,000 | $1,795,000 | $-188,000 | - |
| Other Non Operating Income Expenses | $-37,000 | $-2,528,000 | $-303,000 | - |
| Net Non Operating Interest Income Expense | $66,463,000 | $86,883,000 | $47,482,000 | $9,154,000 |
| Interest Expense Non Operating | $24,231,000 | $0 | $0 | $0 |
| Operating Expense | $1,182,369,000 | $689,524,000 | $498,765,000 | $293,659,000 |
| General And Administrative Expense | $195,037,000 | $97,299,000 | $75,621,000 | $40,586,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Net Interest Income | $66,463,000 | $86,883,000 | $47,482,000 | $9,154,000 |
| Interest Income | $90,694,000 | $86,883,000 | $47,482,000 | $9,154,000 |
| Normalized Income | $-1,115,943,000 | $-604,410,582 | $-436,481,080 | $-248,705,000 |
| Net Income From Continuing And Discontinued Operation | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Total Operating Income As Reported | $-1,182,369,000 | $-689,524,000 | $-487,185,000 | $-258,279,000 |
| Net Income Common Stockholders | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Net Income | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Net Income Including Noncontrolling Interests | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Net Income Continuous Operations | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Pretax Income | $-1,131,301,000 | $-600,846,000 | $-439,891,000 | $-249,125,000 |
| Interest Income Non Operating | $90,694,000 | $86,883,000 | $47,482,000 | $9,154,000 |
| Operating Income | $-1,182,369,000 | $-689,524,000 | $-487,185,000 | $-258,279,000 |
| Per Share | ||||
| Diluted EPS | $-5.95 | $-3.58 | $-3.86 | $-3.08 |
| Basic EPS | $-5.95 | $-3.58 | $-3.86 | $-3.08 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $5,418 | $920 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,075,154,000 | $-593,345,000 | $-430,697,000 | $-248,623,000 |
| Total Unusual Items | $-15,358,000 | $4,323,000 | $115,000 | - |
| Total Unusual Items Excluding Goodwill | $-15,358,000 | $4,323,000 | $115,000 | - |
| Reconciled Depreciation | $16,558,000 | $11,824,000 | $9,309,000 | $9,656,000 |
| EBITDA (Bullshit earnings) | $-1,090,512,000 | $-589,022,000 | $-430,582,000 | $-248,623,000 |
| EBIT | $-1,107,070,000 | $-600,846,000 | $-439,891,000 | $-258,279,000 |
| Diluted Average Shares | $190,129,154 | $167,737,672 | $113,149,869 | $80,626,525 |
| Basic Average Shares | $190,129,154 | $167,737,672 | $113,149,869 | $80,626,525 |
| Diluted NI Availto Com Stockholders | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Tax Provision | $0 | $-753,000 | $-3,524,000 | $-420,000 |
| Gain On Sale Of Security | $-15,358,000 | $4,323,000 | $115,000 | - |
| Research And Development | $987,332,000 | $592,225,000 | $423,144,000 | $253,073,000 |
| Selling General And Administration | $195,037,000 | $97,299,000 | $75,621,000 | $40,586,000 |
| Other Gand A | $195,037,000 | $97,299,000 | $75,621,000 | $40,586,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $0 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,560,889,000 | $2,193,926,000 | $1,753,847,000 | $611,773,000 |
| Total Assets | $2,354,508,000 | $2,558,301,000 | $2,061,705,000 | $811,930,000 |
| Total Non Current Assets | $279,471,000 | $230,669,000 | $182,424,000 | $151,745,000 |
| Other Non Current Assets | $19,637,000 | $5,440,000 | $10,063,000 | $4,594,000 |
| Non Current Prepaid Assets | $24,148,000 | $12,128,000 | - | - |
| Goodwill And Other Intangible Assets | $70,408,000 | $71,278,000 | $72,347,000 | $73,415,000 |
| Other Intangible Assets | $55,800,000 | $56,670,000 | $57,739,000 | $58,807,000 |
| Current Assets | $2,075,037,000 | $2,327,632,000 | $1,879,281,000 | $660,185,000 |
| Other Current Assets | $49,358,000 | $38,333,000 | $25,072,000 | $10,569,000 |
| Cash Cash Equivalents And Short Term Investments | $2,025,679,000 | $2,289,299,000 | $1,852,955,000 | $644,943,000 |
| Cash And Cash Equivalents | $383,745,000 | $543,064,000 | $696,148,000 | $161,412,000 |
| Receivables | - | $0 | $1,254,000 | $4,673,000 |
| Accounts Receivable | - | $0 | $1,254,000 | $4,673,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $158,702,000 | $135,843,000 | $87,944,000 | $64,205,000 |
| Long Term Debt And Capital Lease Obligation | $142,234,000 | $122,971,000 | $80,575,000 | $57,432,000 |
| Current Debt And Capital Lease Obligation | $16,468,000 | $12,872,000 | $7,369,000 | $6,773,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $723,211,000 | $293,097,000 | $235,511,000 | $126,742,000 |
| Total Non Current Liabilities Net Minority Interest | $432,787,000 | $129,183,000 | $91,660,000 | $64,758,000 |
| Other Non Current Liabilities | $269,654,000 | $670,000 | $1,458,000 | $301,000 |
| Derivative Product Liabilities | $18,546,000 | $3,189,000 | $6,512,000 | $0 |
| Non Current Deferred Liabilities | $2,353,000 | $2,353,000 | $3,115,000 | $7,025,000 |
| Non Current Deferred Taxes Liabilities | $2,353,000 | $2,353,000 | $3,115,000 | $7,025,000 |
| Current Liabilities | $290,424,000 | $163,914,000 | $143,851,000 | $61,984,000 |
| Other Current Liabilities | $7,858,000 | $583,000 | $3,896,000 | $505,000 |
| Payables And Accrued Expenses | $207,906,000 | $119,685,000 | $108,973,000 | $36,966,000 |
| Payables | $64,616,000 | $54,427,000 | $61,788,000 | $21,306,000 |
| Accounts Payable | $64,616,000 | $54,427,000 | $61,788,000 | $21,306,000 |
| Current Deferred Liabilities | - | - | $0 | $4,459,000 |
| Equity | ||||
| Common Stock Equity | $1,631,297,000 | $2,265,204,000 | $1,826,194,000 | $685,188,000 |
| Total Equity Gross Minority Interest | $1,631,297,000 | $2,265,204,000 | $1,826,194,000 | $685,188,000 |
| Stockholders Equity | $1,631,297,000 | $2,265,204,000 | $1,826,194,000 | $685,188,000 |
| Gains Losses Not Affecting Retained Earnings | $3,237,000 | $1,321,000 | $544,000 | $-1,780,000 |
| Other Equity Adjustments | $3,237,000 | $1,321,000 | $544,000 | $-1,780,000 |
| Retained Earnings | $-2,869,102,000 | $-1,737,801,000 | $-1,137,708,000 | $-701,341,000 |
| Other | ||||
| Ordinary Shares Number | $197,001,401 | $185,896,625 | $164,674,594 | $90,411,912 |
| Share Issued | $197,001,401 | $185,896,625 | $164,674,594 | $90,411,912 |
| Tangible Book Value | $1,560,889,000 | $2,193,926,000 | $1,753,847,000 | $611,773,000 |
| Invested Capital | $1,631,297,000 | $2,265,204,000 | $1,826,194,000 | $685,188,000 |
| Working Capital | $1,784,613,000 | $2,163,718,000 | $1,735,430,000 | $598,201,000 |
| Capital Lease Obligations | $158,702,000 | $135,843,000 | $87,944,000 | $64,205,000 |
| Total Capitalization | $1,631,297,000 | $2,265,204,000 | $1,826,194,000 | $685,188,000 |
| Additional Paid In Capital | $4,497,143,000 | $4,001,666,000 | $2,963,342,000 | $1,388,300,000 |
| Capital Stock | $19,000 | $18,000 | $16,000 | $9,000 |
| Common Stock | $19,000 | $18,000 | $16,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $142,234,000 | $122,971,000 | $80,575,000 | $57,432,000 |
| Current Capital Lease Obligation | $16,468,000 | $12,872,000 | $7,369,000 | $6,773,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $58,192,000 | $30,774,000 | $23,613,000 | $13,281,000 |
| Current Accrued Expenses | $143,290,000 | $65,258,000 | $47,185,000 | $15,660,000 |
| Goodwill | $14,608,000 | $14,608,000 | $14,608,000 | $14,608,000 |
| Net PPE | $165,278,000 | $141,823,000 | $100,014,000 | $73,736,000 |
| Accumulated Depreciation | $-28,513,000 | $-21,823,000 | $-17,694,000 | $-14,489,000 |
| Gross PPE | $193,791,000 | $163,646,000 | $117,708,000 | $88,225,000 |
| Leases | $22,278,000 | $14,280,000 | $11,952,000 | $11,404,000 |
| Construction In Progress | $54,000 | $394,000 | $513,000 | $0 |
| Other Properties | $162,182,000 | $142,726,000 | $98,654,000 | $72,240,000 |
| Machinery Furniture Equipment | $9,277,000 | $6,246,000 | $6,589,000 | $4,581,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $1,641,934,000 | $1,746,235,000 | $1,156,807,000 | $483,531,000 |
| Treasury Shares Number | - | $0 | - | - |
| Current Deferred Revenue | - | - | $0 | $4,459,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-913,731,000 | $-567,744,000 | $-358,301,000 | $-235,217,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-897,741,000 | $-557,436,000 | $-350,572,000 | $-224,401,000 |
| Cash Flow From Continuing Operating Activities | $-897,741,000 | $-557,436,000 | $-350,572,000 | $-224,401,000 |
| Operating Gains Losses | $15,390,000 | $-4,205,000 | $167,000 | $19,000 |
| Investing Activities | ||||
| Capital Expenditure | $-15,990,000 | $-10,308,000 | $-7,729,000 | $-10,816,000 |
| Investing Cash Flow | $118,058,000 | $-554,394,000 | $-342,598,000 | $-24,116,000 |
| Cash Flow From Continuing Investing Activities | $118,058,000 | $-554,394,000 | $-342,598,000 | $-24,116,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $347,915,000 | $846,348,000 | $385,759,000 | $298,045,000 |
| Financing Cash Flow | $621,524,000 | $959,413,000 | $1,229,200,000 | $301,432,000 |
| Cash Flow From Continuing Financing Activities | $621,524,000 | $959,413,000 | $1,229,200,000 | $301,432,000 |
| Net Other Financing Charges | $220,000 | $284,000 | $836,808,000 | $42,000 |
| Net Common Stock Issuance | $347,915,000 | $846,348,000 | $385,759,000 | $298,045,000 |
| Common Stock Issuance | $347,915,000 | $846,348,000 | $385,759,000 | $298,045,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $388,603,000 | $546,762,000 | $699,179,000 | $163,149,000 |
| Beginning Cash Position | $546,762,000 | $699,179,000 | $163,149,000 | $110,234,000 |
| Changes In Cash | $-158,159,000 | $-152,417,000 | $536,030,000 | $52,915,000 |
| Proceeds From Stock Option Exercised | $273,389,000 | $112,781,000 | $6,633,000 | $3,345,000 |
| Net Investment Purchase And Sale | $134,048,000 | $-544,086,000 | $-334,869,000 | $-13,300,000 |
| Sale Of Investment | $1,928,898,000 | $1,592,537,000 | $724,047,000 | $599,469,000 |
| Purchase Of Investment | $-1,794,850,000 | $-2,136,623,000 | $-1,058,916,000 | $-612,769,000 |
| Net PPE Purchase And Sale | $-15,990,000 | $-10,308,000 | $-7,729,000 | $-10,816,000 |
| Purchase Of PPE | $-15,990,000 | $-10,308,000 | $-7,729,000 | $-10,816,000 |
| Change In Working Capital | $86,823,000 | $406,000 | $36,752,000 | $-13,489,000 |
| Change In Other Current Liabilities | $-420,000 | $-33,000 | $-1,375,000 | $-2,618,000 |
| Change In Other Current Assets | $-12,872,000 | $1,688,000 | $870,000 | $-2,247,000 |
| Change In Payables And Accrued Expense | $121,802,000 | $15,520,000 | $47,137,000 | $8,790,000 |
| Change In Accrued Expense | $112,267,000 | $21,985,000 | $14,668,000 | $1,502,000 |
| Change In Payable | $9,535,000 | $-6,465,000 | $32,469,000 | $7,288,000 |
| Change In Account Payable | $9,535,000 | $-6,465,000 | $32,469,000 | $7,288,000 |
| Change In Prepaid Assets | $-21,687,000 | $-17,261,000 | $-4,930,000 | $-3,779,000 |
| Change In Receivables | $0 | $1,254,000 | $3,419,000 | $1,256,000 |
| Changes In Account Receivables | $0 | $1,254,000 | $3,419,000 | $1,256,000 |
| Other Non Cash Items | $24,231,000 | - | - | - |
| Stock Based Compensation | $118,389,000 | $79,197,000 | $61,772,000 | $31,196,000 |
| Amortization Of Securities | $-27,831,000 | $-44,565,000 | $-22,205,000 | $-3,078,000 |
| Depreciation Amortization Depletion | $16,558,000 | $11,824,000 | $9,309,000 | $9,656,000 |
| Depreciation And Amortization | $16,558,000 | $11,824,000 | $9,309,000 | $9,656,000 |
| Amortization Cash Flow | $870,000 | $1,069,000 | $1,068,000 | $1,069,000 |
| Amortization Of Intangibles | $870,000 | $1,069,000 | $1,068,000 | $1,069,000 |
| Depreciation | $15,688,000 | $10,755,000 | $8,241,000 | $8,587,000 |
| Gain Loss On Investment Securities | $15,358,000 | $-4,323,000 | $115,000 | - |
| Gain Loss On Sale Of PPE | $32,000 | $118,000 | $52,000 | $19,000 |
| Net Income From Continuing Operations | $-1,131,301,000 | $-600,093,000 | $-436,367,000 | $-248,705,000 |
| Change In Other Working Capital | - | $-762,000 | $-8,369,000 | $-14,891,000 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-15